奥沙利铂与吡喃阿霉素介入治疗原发性肝癌疗效及安全性.docVIP

奥沙利铂与吡喃阿霉素介入治疗原发性肝癌疗效及安全性 　　【摘要】 目的：对比分析原发性肝癌采用奥沙利铂和吡喃阿霉素介入治疗的疗效与安全性。方法：选取本院2009年1月-2012年12月收治的76例原发性肝癌患者作为研究对象，按照随机数字表法将其分为为研究组与对照组各38例。研究组患者采取吡喃阿霉素介入治疗，对照组则采取奥沙利铂介入治疗。观察比较两组患者治疗效果与安全性，疗效包括总有效率、疾病控制率、临床症状改善率、肿瘤标志物的下降率、疾病进展时间、不良反应发生率等；分析两组中进展时间大于12个月的患者情况，来判断介入治疗远期疗效的影响因素。结果：研究组治疗总有效率、平均疾病无进展时间和肿瘤标志物下降率均明显优于对照组，比较差异有统计学意义（P0.05）。通过分析可知，介入治疗远期疗效的影响因素包括门静脉受累、病灶有无包膜及术后合并应用抗癌药物等。结论：原发性肝癌患者采用吡喃阿霉素介入治疗，有着安全与有效的优势，同时能提高疾病无进展时间，相较于吡喃阿霉素介入治疗效果更佳，值得临床推广及应用。 　　【关键词】 奥沙利铂； 吡喃阿霉素； 介入治疗； 原发性肝癌； 疗效； 安全性 　　Efficacy and Safety of Oxaliplatin and Pirarubicin Intervention in the Treatment of Primary Liver Cancer/LIU Xiao-hong，WAN Lin-lin，DING Wei，et al.//Medical Innovation of China，2013，10（35）：021-023 　　【Abstract】 Objective：To analyze and compare the efficacy and safety of Oxaliplatin and Pirarubicin intervention on primary liver cancer.Method：Seventy-six primary liver cancer patients in our hospital from January 2009 to December 2012 were selected as the research objects，and then randomly divided into the study group and the control group，38 cases in each group.The study group was treated with pirarubicin intervention，the control group was treated with interventional therapy.The effect and safety comparison of two groups were analyzed，including the incidence of clinical total effective rate，disease control rate，clinical symptom improvement rate of decline，the rate of tumor markers，time to progression，adverse reaction；Time to progression than patients in the two groups of 12 months were analyzed，and determined the factors that affect on the long-term effect of interventional therapy Result：The total effective rate，average progression free survival and tumor marker decline rate of the treatment group were better than those of the control group，the differences were statistically significant （P0.05）.Through the analysis，factors affecting the long-term effect of interventional treatment，including portal vein involvement，lesions were non enveloped and postoperative combined with antic